On December 24, Denis Manturov, Deputy Prime Minister of the Russian Federation - Minister of Industry and Trade of the Russian Federation, and Radiy Khabirov, Head of the Republic of Bashkortostan, launched the manufacturing of Blood Coagulation Factor VIII at Pharmstandard-UfaVITA plant. The launch ceremony was held via video teleconference from the Management Center of the Republic of Bashkortostan.

Plasma-derived haemostatic agent corresponding to INN Blood Coagulation Factor VIII is necessary to treat haemophilia, a rare orphan disease that causes blood-clotting disorder. This is the first Russia’s large-scale local manufacturing of this product for prevention and treatment of haemophilia A included in the list of vital and essential drugs.

“Pharmstandard is taking another step towards scaling up its plant in Ufa. It is worth reminding that in the tough time of the pandemic this site was one of the main facilities for manufacturing Sputnik vaccines and anti-COVID drugs. In general, the enterprise is of great importance for the industry,” noted Denis Manturov, Deputy Prime Minister - Minister of Industry and Trade of Russia.

“Medicines made from human-donated plasma help to save lives and boost immunity. This is why the blood product manufacturing in Russia and supplying to our citizens is one of our most essential tasks in the field of pharmaceuticals industry,” stressed Denis Manturov.

Radiy Khabirov, Head of the Republic of Bashkortostan thanked the Ministry of Industry and Trade of the RF and Pharmstandard team for the development of this critical production sphere: “We are always glad when a new production is launched in our republic. Today Pharmstandard-UfaVITA is being developed with the support of the Ministry of Industry and Trade of Russia. Dear Denis Valentinovich, thank you for this support. I also highly appreciate the contribution of the company’s team that keeps making progress and implements five investment projects. The launching of this new production line is a great New Year’s present for all of us.”

Grigory Potapov, CEO of JSC “Pharmstandard”, rated highly the significance of the project implemented in Ufa. “We constantly invest in cutting-edge developments and implement state-of-the-art manufacturing technologies. This enables us to provide for the needs of public health services in medicinal products. At Pharmstandard-UfaVITA site, we implement the import substitution program,” stated Grigory Potapov. “The innovative product that will be manufactured here will make it possible to improve the quality of life of more than 10 thousand Russian patients.”

At the command from the Republic Management Centre, Nail Nizamutdinov, General Director of Pharmstandard-UfaVITA, launched the manufacturing.

1.6 billion rubles were invested in the project implementation. The production line capacity is 500 thousand packs per year. In the longer term, it is planned to develop export supplies of the new product.